System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Editorial Ppublish

PubMed: 42873890 DOI: 10.1126/scitranslmed.aeg5988

Rifampicin-resistant TB: An inflection point in antimicrobial resistance.

Sci Transl Med 18(871):eaeg5988

Authors: Cesar Augusto Roque-Borda, João Perdigão, Fernando Rogério Pavan

Affiliations

  • Cesar Augusto Roque-Borda is a postdoctoral researcher in the School of Pharmaceutical Sciences, Sao Paulo State University, Sao Paulo, Brazil, and associate researcher in the Vice-Rectorate for Research of the Catholic University of Santa María, Arequipa, Peru.
  • João Perdigão is an assistant professor in the Institute for Medicines Research, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
  • Fernando Rogério Pavan is an associate professor in the School of Pharmaceutical Sciences, Sao Paulo State University, Sao Paulo, Brazil.
  • Cesar Augusto Roque-Borda is a postdoctoral researcher in the School of Pharmaceutical Sciences, Sao Paulo State University, Sao Paulo, Brazil, and associate researcher in the Vice-Rectorate for Research of the Catholic University of Santa María, Arequipa, Peru. João Perdigão is an assistant professor in the Institute for Medicines Research, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal. Fernando Rogério Pavan is an associate professor in the School of Pharmaceutical Sciences, Sao Paulo State University, Sao Paulo, Brazil.

Abstract

Rifampicin-resistant TB should be integrated into the global AMR response through diagnostics, surveillance, and optimized treatment regimens.

MeSH

Rifampin